Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

BDSX 10.18.2024

Full Press ReleaseSEC FilingsOur BDSX Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
  • 01.07.2025 - Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
  • 11.21.2024 - Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum

Recent Filings

  • 01.10.2025 - EX-99.1 EX-99.1
  • 01.10.2025 - 8-K Current report
  • 11.22.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

LOUISVILLE, Colo.--(BUSINESS WIRE)--Oct. 18, 2024--Biodesix, Inc.(Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter endedSeptember 30, 2024before the start of trading onFriday, November 1.Biodesixmanagement will host a conference call and webcast to discuss its financial results and provide a general business update at8:30 a.m. Eastern Timeon the same day.

Listeners can register for the webcast via thislink. Analysts who wish to participate in the question and answer session should use thislink. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.

AboutBiodesix

Biodesixis a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung®Nodule Risk Assessment evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLungTM test portfolio for lung cancer patients integrates the GeneStrat®targeted ddPCRTM test, the GeneStrat NGS®test, and the VeriStrat®test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition,Biodesixcollaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visitbiodesix.com.

Note:Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks ofBiodesix, Inc.ddPCR is a trademark of Bio-Rad Laboratories, Inc.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors.Biodesixhas based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, expectations regarding revenue and margin growth and its impact on profitability, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, onBiodesixand its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section ofBiodesixmost recent annual report on Form 10-K, filedMarch 1, 2024.Biodesixundertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241018266313/en/

Media:Natalie St. Denis[email protected]1-720-925-9285

Investors:Chris Brinzey[email protected](339) 970-2843

Source:Biodesix, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com